Antibody-Drug Conjugate Toxicity Review with Clinical Algorithms

Antonio De Palma's review summarizes mechanisms and management of adverse events from EMA-approved antibody-drug conjugates (ADCs). The work includes operational algorithms and flowcharts for clinical decision-making, based on evidence from pivotal trials, regulatory documents, and literature up to January 2025. The dataset consists of PDF and JPEG files totaling 427.2 KB.

Use Cases

• Develop clinical decision-support tools based on the included toxicity-management algorithms.
• Summarize evidence on specific adverse events like ILD/pneumonitis or ocular toxicity from the reviewed literature.
• Train healthcare professionals on structured monitoring pathways for ADC toxicities.
• Inform the design of clinical trials by referencing the summarized toxicity profiles of approved agents.

Strengths

• Includes operational algorithms and flowcharts designed for real-world clinical use.
• Synthesizes evidence from regulatory documents, clinical trials, and emerging literature up to January 2025.
• Focuses on EMA-approved agents and their most frequent or severe adverse events.

Limitations

• Dataset is a 427.2 KB review document, not a structured data table; row and column counts are unknown.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect the temporal and source bias inherent to the literature review methodology.

Provenance

Source

Antonio De Palma via figshare.

Collection Method

Literature review identified through PubMed and EMBASE searches, regulatory Summary of Product Characteristics (SmPCs), and key clinical trials.

Time Range

Literature reviewed up to January 2025.

Freshness

Last updated 2026-06-03 15:18:16; freshness should be verified.